Medullary Thyroid Cancer (MTC) Completed Phase 1 Trials for Everolimus (DB01590)

Back to Medullary Thyroid Cancer (MTC)

Also known as: Thyroid Carcinoma, Medullary / Medullary carcinoma of thyroid / Thyroid Gland Medullary Carcinoma / Thyroid Medullary Carcinoma / Thyroid Cancer, Medullary / Medullary Thyroid Carcinoma / Medullary Thyroid Cancer / Medullary thyroid carcinoma (disorder) / Medullary carcinoma with amyloid stroma (morphologic abnormality) / Parafollicular cell carcinoma (disorder) / Medullary thyroid carcinoma (morphologic abnormality) / C cell neuroendocrine neoplasm / Parafollicular cell carcinoma / C cell carcinoma / Ultimobranchial thyroid tumor / Ultimobranchial thyroid tumour / MTC - Medullary thyroid carcinoma / Medullary carcinoma with amyloid stroma -RETIRED-

Indication	Status	Phase
DBCOND0062236 (Medullary Thyroid Cancer (MTC))	Completed	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT00655655	Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors	Treatment	Everolimus (DB01590) Vatalanib (DB04879)
NCT01204476	Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma	Treatment	Cixutumumab (DB12250) Everolimus (DB01590) Octreotide (DB00104)